**Figure B, Supplemental Digital Content 2.** Enrollment, exposure assignment, and follow-up of study population. ZDV zidovudine, FF formula-feeding, BF breastfeeding, HAART highly-active antiretroviral therapy.

a A second-born twin whose first-born sibling was stillborn is included in the analysis

1930 HIV-infected pregnant women in enrolled in Mashi and Mma Bana studies

1877 Live first-born infants

assigned exposure

13 Lost to Follow-up prior to delivery

2 Maternal deaths prior to delivery

38 Stillbirths

22 Second-born twinsa

591 infants with assigned exposure to maternal

ZDV and formula-feeding

51 HIV-infected

34 Exposed to antenatal HAART

 588 infants with assigned exposure to maternal

ZDV and breastfeeding

698 infants with assigned exposure to maternal HAART and breastfeeding

503 Infants included in analysis for ZDV-BF

525 Infants included in analysis for ZDV-FF

691 Infants included in analysis for HAART-BF

56 Infants not included for primary endpoint (10.6%)

 38 Infant deaths

 18 Lost to follow-up

34 Infants not included for primary endpoint (6.7%)

 15 Infant deaths

 19 Lost to follow-up

36 Infants not included for primary endpoint (5.2%)

 18 Infant deaths

 18 Lost to follow-up

7 HIV-infectedb

32 HIV-infectedc

34 Exposed to antenatal HAART

b Does not include a second-born, HIV-infected twin in the Mma Bana study.

c Includes two HIV-infected infants exposed to antenatal HAART.